For example, the reported association of TFCP2 fusion positive SCS-RMS with ALK overexpression might suggest a role for ALK inhibitors, although the potential benefits of ALK inhibition in this tumor type need to be further addressed [64]. This evidence concerns the gene ALK and neoplasm.